Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Cancer

Volumn 121, Issue 21, 2015, Pages 3894-3904

  Yilmaz, Musa ^a   Lahoti, Amit ^b   O'Brien, Susan ^b   Nogueras González, Graciela M ^b   Burger, Jan ^b   Ferrajoli, Alessandra ^b   Borthakur, Gautam ^b   Ravandi, Farhad ^b   Pierce, Sherry ^b   Jabbour, Elias ^b   Kantarjian, Hagop ^b   Cortes, Jorge E ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

chronic myeloid leukemia (CML); dasatinib; glomerular filtration rate changes; imatinib; kidney injury; nilotinib; outcome; tyrosine kinase inhibitor

Indexed keywords

CREATININE; DASATINIB; IMATINIB; NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC KIDNEY DISEASE; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOGENETICS; DIABETES MELLITUS; DRUG MEGADOSE; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; ACUTE KIDNEY INJURY; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; KIDNEY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CREATININE; DASATINIB; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMATINIB MESYLATE; INCIDENCE; KIDNEY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84945490814     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29587     Document Type: Article

References (47)

1. O'Brien SG, Guilhot F, Larson RA, et al., Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994-1004.
2. Kantarjian H, Giles F, Wunderle L, et al., Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354: 2542-2551.
3. Talpaz M, Shah NP, Kantarjian H, et al., Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354: 2531-2541.
4. Cortes JE, Jones D, O'Brien S, et al., Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010; 28: 392-397.
5. Kantarjian HM, Shah NP, Cortes JE, et al., Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012; 119: 1123-1129.
6. Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM,. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003; 98: 437-457.
7. Manley PW, Stiefl N, Cowan-Jacob SW, et al., Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem. 2010; 18: 6977-6986.
8. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC,. Dysregulation of bone remodeling by imatinib mesylate. Blood. 2010; 115: 766-774.
9. Deininger MW, O'Brien SG, Ford JM, Druker BJ,. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003; 21: 1637-1647.
10. Al-Kali A, Farooq S, Tfayli A,. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. J Clin Pharm Ther. 2009; 34: 607-610.
11. Foringer JR, Verani RR, Tjia VM, Finkel KW, Samuels JA, Guntupalli JS,. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother. 2005; 39: 2136-2138.
12. Kitiyakara C, Atichartakarn V,. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant. 2002; 17: 685-687.
13. Pinder EM, Atwal GS, Ayantunde AA, et al., Tumour lysis syndrome occurring in a patient with metastatic gastrointestinal stromal tumour treated with Glivec (imatinib mesylate, Gleevec, STI571). Sarcoma. 2007; 2007: 82012.
14. Pou M, Saval N, Vera M, et al., Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma. 2003; 44: 1239-1241.
15. Vora A, Bhutani M, Sharma A, Raina V,. Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase. Ann Oncol. 2002; 13: 1833-1834.
16. Perazella MA,. Drug-induced nephropathy: an update. Expert Opin Drug Saf. 2005; 4: 689-706.
17. Nakagawa T, Sasahara M, Haneda M, et al., Role of PDGF B-chain and PDGF receptors in rat tubular regeneration after acute injury. Am J Pathol. 1999; 155: 1689-1699.
18. Marcolino MS, Boersma E, Clementino NC, et al., Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol. 2011; 22: 2073-2079.
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461-470.
20. Mehta RL, Kellum JA, Shah SV, et al., Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007; 11: R31.
21. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39 (suppl 1): S1-S266.
22. Kantarjian H, Sawyers C, Hochhaus A, et al., Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645-652.
23. Sokal JE, Cox EB, Baccarani M, et al., Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984; 63: 789-799.
24. National Comprehensive Cancer Network. Chronic myelogenous leukemia. Version 1.2014. http://www.nccn.org/patients/guidelines/cml/index.html. Accessed June 2015.
25. Ali R, Ozkalemkas F, Ozkan A, et al., Tumour lysis syndrome with acute renal failure during imatinib therapy. Leuk Res. 2007; 31: 573-574.
26. Gafter-Gvili A, Ram R, Gafter U, Shpilberg O, Raanani P,. Renal failure associated with tyrosine kinase inhibitors-case report and review of the literature. Leuk Res. 2010; 34: 123-127.
27. Takikita-Suzuki M, Haneda M, Sasahara M, et al., Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury. Am J Pathol. 2003; 163: 277-286.
28. Floege J, Eitner F, Alpers CE,. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol. 2008; 19: 12-23.
29. Kishioka H, Fukuda N, Wen-Yang H, Nakayama M, Watanabe Y, Kanmatsuse K,. Effects of PDGF A-chain antisense oligodeoxynucleotides on growth of cardiovascular organs in stroke-prone spontaneously hypertensive rats. Am J Hypertens. 2001; 14 (pt 1): 439-445.
30. Johnson RJ, Raines EW, Floege J, et al., Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med. 1992; 175: 1413-1416.
31. Nakamura H, Isaka Y, Tsujie M, et al., Electroporation-mediated PDGF receptor-IgG chimera gene transfer ameliorates experimental glomerulonephritis. Kidney Int. 2001; 59: 2134-2145.
32. Takahashi T, Abe H, Arai H, et al., Activation of STAT3/Smad1 is a key signaling pathway for progression to glomerulosclerosis in experimental glomerulonephritis. J Biol Chem. 2005; 280: 7100-7106.
33. Floege J, Ostendorf T, Janssen U, et al., Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol. 1999; 154: 169-179.
34. Ostendorf T, Kunter U, Grone HJ, et al., Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol. 2001; 12: 909-918.
35. Boor P, Konieczny A, Villa L, et al., PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrol Dial Transplant. 2007; 22: 1323-1331.
36. Gilbert RE, Kelly DJ, McKay T, et al., PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int. 2001; 59: 1324-1332.
37. Lassila M, Jandeleit-Dahm K, Seah KK, et al., Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol. 2005; 16: 363-373.
38. Zoja C, Corna D, Rottoli D, Zanchi C, Abbate M, Remuzzi G,. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int. 2006; 70: 97-103.
39. Schellings MW, Baumann M, van Leeuwen RE, et al., Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension. 2006; 47: 467-474.
40. Savikko J, Taskinen E, Von Willebrand E,. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation. 2003; 75: 1147-1153.
41. Floege J, Johnson RJ,. Multiple roles for platelet-derived growth factor in renal disease. Miner Electrolyte Metab. 1995; 21: 271-282.
42. Shultz PJ, DiCorleto PE, Silver BJ, Abboud HE,. Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am J Physiol. 1988; 255: F674-F684.
43. Floege J, Johnson RJ, Alpers CE, et al., Visceral glomerular epithelial cells can proliferate in vivo and synthesize platelet-derived growth factor B-chain. Am J Pathol. 1993; 142: 637-650.
44. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ,. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci U S A. 1992; 89: 2873-2877.
45. Iyoda M, Shibata T, Hirai Y, Kuno Y, Akizawa T,. Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. J Am Soc Nephrol. 2011; 22: 1486-1496.
46. Bolignano D, Mattace-Raso F, Sijbrands EJ, Zoccali C,. The aging kidney revisited: a systematic review. Ageing Res Rev. 2014; 14: 65-80.
47. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M,. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int. 2007; 72: 632-637.